Trial
NCT01517347
Efficiency Study of Low Dose of IL-2 to Prevent Relapse in Standard Risk Leukemia After Transplantation
UnknownTERMINATEDEFFICACY/FUTILITYConfidence: HIGH
Sponsor
Peking University People's Hospital
Collaborators
—
Condition
Leukemia
Intervention
Interleukin-2
Why stopped
Because the conditional power was 0.083, the Data and Safety Monitoring Board recommended halting the study due to futility after the 1st interim analysis.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2016-10-24